A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

Part of paid clinical trials in Fresno, California.

Sponsor
MediWound Ltd
Study ID
NCT06568627
Phase
PHASE3
Status
Recruiting

Conditions

  • Venous Leg Ulcer (VLU)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • EscharEx (EX-03) — DRUG
    a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
  • Placebo (Gel vehicle) — DRUG
    A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area

Study Details

The main objective of this study is: To assess the efficacy and safety of EscharEx (EX-03 5% formulation) compared to placebo control,in debridement and wound bed preparation of Venous Leg Ulcers (VLU).

Key Dates

Start date
Jun 1, 2025
Status verified
Mar 2026
Primary completion
Dec 31, 2026
Completion
Mar 31, 2027

Study Design

Enrollment
216 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: EscharEx (EX-03)
    EX-03 is the code name of the third generation of EscharEx investigational medicinal product (IMP) formulation. A sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb ), the active pharmaceutical ingredient (API), that is blended with excipients. EX-03 5% powder, should be diluted with Water for Injection (WFI) prior usage.
  • Placebo Comparator: Placebo
    Placebo (Gel Vehicle, hydrogel) contains the same excipients as in EX-03, without the API. Placebo powder, should be diluted with Water for Injection (WFI) prior usage.

Primary Outcome Measure

Incidence of complete debridement, clinically (visually) assessed after each application [ Time Frame: up to 2 weeks ]

Central Contacts

Locations (14)

FacilityCityStateZIPSite coordinators
Limb Preservation Platform, IncFresnoCalifornia93710
Destiny Blackstone, SC
(800) 714-8011
Shawn Cazzell, DPM (PRINCIPAL_INVESTIGATOR)
Angel City Research,IncLos AngelesCalifornia90010
Maira Jackson, SC
213-631-0596
Joanna Cuevas, SC
213-365-0793
Felix Sigal, MD (PRINCIPAL_INVESTIGATOR)
Center for Clinical Research INCSan FranciscoCalifornia94115
Maria Peralta, SC
(800) 363-1069
Gayana Sarkisova, SC
(800) 363-1069
Alexander Reyzelman, DPM (PRINCIPAL_INVESTIGATOR)
Mher Vartivarian, DPM (SUB_INVESTIGATOR)
ILD Research CenterVistaCalifornia92081
Eric Martinez, SC
760-350-5080
Yani Manaznares, SC
760-350-5080
Dean Dean Vayser, MD (PRINCIPAL_INVESTIGATOR)
University of MiamiMiamiFlorida33136
Aliette Espinosa, SC
305-689-3376
Leonela Espinoza, SC
305-689-3376
Robert Kirsner, MD (PRINCIPAL_INVESTIGATOR)
Boston Medical CenterBostonMassachusetts02118
Pedro Jardim, SC
617-414-8092
Emily Meng, SC
617-414-8092
Elizabeth Sanders, MD (PRINCIPAL_INVESTIGATOR)
Massachusetts General HospitalBostonMassachusetts02114
Matthew Supple, SC
617-726-3712
Daniela Requena, SC
617-726-3712
Jeremy Goverman, MD (PRINCIPAL_INVESTIGATOR)
Rutgers New Jersey Medical CenterNewarkNew Jersey07103
Saharsh Patel, SC
973-972-3173
Mehreen Bhatti, SC
(973) 972-5435
Alex Wong, MD (PRINCIPAL_INVESTIGATOR)
Northwell Health Comprehensive Wound Healing CenterLake SuccessNew York11042-
NYU Langone Health Long Island - Research & Academic CenterMineolaNew York11501
Monica Benitez, SC
516-969-6120
Anita Farhi, SC
516-663-9582
Scott Gorenstein, MD (PRINCIPAL_INVESTIGATOR)
Mount Sinai WestNew YorkNew York10019
Tianyi Yang, SC
212-523-8195
Garismar Ramirez, SC
212-523-8195
Michael Michael Dudkiewicz, MD (PRINCIPAL_INVESTIGATOR)
John Lantis, MD (SUB_INVESTIGATOR)
Mary Bridge, MD (SUB_INVESTIGATOR)
Cutting Edge Research LLC.,CirclevilleOhio43113
Marie Liden
614-519-7845
Brock Liden, MD (PRINCIPAL_INVESTIGATOR)
Clinical Trial Network HoustonHoustonTexas77074
Shafae Saleem, SC
713-484-6947
David Coreas, SC
713-484-6947
Ullabritt Larka, MD (PRINCIPAL_INVESTIGATOR)
Woundcentrics, LLCSan AntonioTexas78251
Tarek Ibrahim, SC
210-703-8454
Jhemima Rizalde, SC
702-427-4653
Marcus Gitterle, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Fresno, CA

Related Studies